A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer

Shinnosuke Ikemura, Katsuhiko Naoki, Hiroyuki Yasuda, Ichiro Kawada, Satoshi Yoda, Hideki Terai, Takashi Sato, Kota Ishioka, Daisuke Arai, Keiko Ohgino, Hirofumi Kamata, Jun Miyata, Hiroki Kabata, Tomoko Betsuyaku, Kenzo Soejima

研究成果: Article査読

4 被引用数 (Scopus)

抄録

Objective: This Phase II studywas conducted to evaluate the efficacy and safety of S-1 and irinotecan combination therapy as a second-line treatment in patients with advanced non-small cell lung cancer. Methods: Irinotecan was administered at 60 mg/m2 on Days 1 and 8. Oral S-1 was administered on Days 1-14 every 3 weeks at 80 mg/day for patients with a body surface area of <1.25 m2, 100 mg/day for patients with a body surface area of 1.25-1.5 m2 and 120 mg/day for patients with a body surface area of >1.5 m2. The primary endpoint was response rate, while the secondary endpoints were progression-free survival, overall survival and safety. Results: Thirty-one patientswere enrolled in this study. The response and disease control rateswere 6.5 and 58.1%, respectively. Progression-free survival and median survival time were 2.8 and 12.6 months, respectively. Grade 3-4 adverse events were reported for 29.0% of the patients. Hematological toxicities of Grade 3 or 4 included leukopenia (9.7%), neutropenia (9.7%), febrile neutropenia (3.2%), thrombopenia (3.2%) and anemia (6.5%). Non-hematological toxicities of Grade 3 or 4 included pneumonitis (6.5%), diarrhea, colitis, dyspnea, rash, oral mucositis, anorexia and pulmonary thromboembolism/deep vein thrombosis (3.2% each). Conclusions: S-1 and irinotecan combination therapy at the present dose and schedule exhibited only modest efficacy with mild toxicities in previously treated patients with non-small cell lung cancer. No further clinical investigation with current dose and schedules is warranted for patients with non-small cell lung cancer who failed first-line platinum-based doublet chemotherapy.

本文言語English
ページ(範囲)356-361
ページ数6
ジャーナルJapanese journal of clinical oncology
45
4
DOI
出版ステータスPublished - 2015 4 1
外部発表はい

ASJC Scopus subject areas

  • 腫瘍学
  • 放射線学、核医学およびイメージング
  • 癌研究

フィンガープリント

「A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル